Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 485 DKK 1.57%
Market Cap: 98.3B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Total Equity
kr31B
CAGR 3-Years
15%
CAGR 5-Years
30%
CAGR 10-Years
33%
Zealand Pharma A/S
CSE:ZEAL
Total Equity
kr8.9B
CAGR 3-Years
96%
CAGR 5-Years
45%
CAGR 10-Years
40%
Ascendis Pharma A/S
NASDAQ:ASND
Total Equity
-€97.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Total Equity
kr10.4B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
27%
Bioporto A/S
CSE:BIOPOR
Total Equity
kr104.8m
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
12%
Saniona AB
STO:SANION
Total Equity
kr6.9m
CAGR 3-Years
-75%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology
Economic Moat
Narrow

In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.

GMAB Intrinsic Value
2 682.76 DKK
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Genmab A/S's Total Equity?
Total Equity
31B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Total Equity amounts to 31B DKK.

What is Genmab A/S's Total Equity growth rate?
Total Equity CAGR 10Y
33%

Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Genmab A/S have been 15% over the past three years , 30% over the past five years , and 33% over the past ten years .

Back to Top